Randy Everett Email

Senior Director, Field Medical Training & Development . Epizyme

Current Roles

Employees:
270
Revenue:
$34.2M
About
Epizyme, Inc. is a late-stage biopharmaceutical company rewriting therapy for cancer and other serious diseases through novel epigenetic medicines. Our pipeline is led by tazemetostat, an investigational agent that is an orally administered, first-in-class small molecule EZH2 inhibitor for the treatment of multiple types of hematological malignancies and genetically defined solid tumors. The company also is developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them.
Epizyme Address
400 Technology Square
Cambridge, MA
United States
Epizyme Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.